Biogen Inc. (BIIB)
NASDAQ • Healthcare
Last close at September 30, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Biogen Inc. keeps $4 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 28
in 28 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Biogen beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 29. Revenue of about $2.7 billion topped the about $2.5 billion consensus by about 11% and rose 3.4% from about $2.6 billion a year ago, while adjusted EPS of $3.60 beat the $2.94 estimate by about 22% and was down 34.2% from $5.47 a year ago. The quarter generated gross profit of about $1.6 billion and operating income of roughly $318.1 million, leaving gross margin near 57% and operating margin about 12%. Net income fell 84.6% to roughly $97.5 million from about $634.8 million a year ago, and operating cash flow came in at about $448.9 million. Next-period consensus calls for EPS of $2.09 on revenue of $2.63 billion.
Next report — what to expect
Biogen Inc. (BIIB) reports next on October 28, 2026. Wall Street expects EPS of $2.03 on revenue of $2.64 billion. For trailing context, revenue grew +3.4% year over year last quarter. Biogen has beaten EPS in 8 of 8 most recent quarters, keeping focus on profit and sales delivery.
About Biogen Inc.
Biogen Inc. develops, manufactures, and markets therapies for neurological, neurodegenerative, autoimmune, and blood-related diseases. Listed on NASDAQ as BIIB, the company sits within the healthcare sector as a branded drug maker, and it recorded $9.8 billion in revenue in FY2025.
Today's Snapshot
BIIB closed 0.5% lower at 225.88, in line with a weaker sector. At the close, BIIB was within 2% of its 52-week high of 230.49.
Trading Volume
Above 10d avg 1.3M
1.5M
vs S&P 500 Today
Underperforming Market
-0.71%
Updated: September 30, 2026 at 20:22 UTC
BIIB Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$194.59 - $224.55Buy
- RSI (14)58.93Neutral
- Stochastic %K (14, 3, 3)82.86Sell
- MACD Level (12, 26)3.57Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.